LGND
Ligand Pharmaceuticals Incorporated
290.10$
+2.3%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.4% | +51.5% | +29.5% | +78.2% | -52.2% | +36.0% | +47.7% | -18.8% | -33.1% | +27.3% | +60.4% | |
| – | -36.4% | -4.1% | -3.7% | +18.1% | +79.1% | +168.1% | +104.4% | -15.0% | -33.7% | -68.4% | -40.5% | |
| – | +19.3% | +56.4% | +31.3% | +80.6% | -55.6% | +22.2% | +34.7% | -20.0% | -32.9% | +62.1% | +67.6% | |
| – | +10.4% | +58.6% | +26.7% | +3.6% | +100.7% | -27.6% | -20.7% | +12.4% | -32.0% | -12.7% | +278.9% | |
| – | +8.0% | +9.2% | +7.6% | +31.7% | +11.0% | +43.3% | -22.0% | +49.7% | -24.7% | +49.0% | +17.5% | |
| – | +8.8% | +54.9% | +15.7% | +20.3% | -957.8% | – | -21.0% | +85.9% | -39.9% | +111.9% | +19.9% | |
| – | +39.2% | +60.6% | +55.1% | +140.5% | +392.9% | -95.4% | +176.9% | -97.1% | +293.2% | -289.3% | – | |
| – | +142.8% | +3.2% | -6.4% | +323.5% | -26.0% | -23.3% | -28.4% | -90.8% | -63.5% | +363.0% | +55.3% | |
| – | +212.6% | -77.5% | +619.0% | +202.9% | +359.6% | -99.8% | +5,488.6% | -50.1% | +76.8% | -96.0% | +6,212.9% | |
| – | -53,660.0% | – | +332.6% | -32.8% | +457.6% | -103.2% | – | – | -76.1% | -33.4% | +426.8% | |
| – | +2,039.9% | -100.6% | – | +1,041.5% | +339.1% | -100.5% | – | -158.4% | – | -107.7% | – | |
| – | +28.2% | +84.2% | +47.1% | +193.6% | +267.7% | -93.5% | +151.9% | -43.1% | +24.2% | -59.5% | +372.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.